McKechnie Duncan

EVP McKechnie Duncan sells 2,633 VRTX shares at $498.42; third sale in 7 days, post-transaction holdings drop to 12,489 shares

McKechnie Duncan, Chief Commercial Officer, executed the third consecutive open-market sale of VERTEX PHARMACEUTICALS stock within seven days (prior sales on 2026-03-04 and 2026-02-25), selling 2,633 shares at $498.42 on 2026-03-11 for $1,312,339.86. His post-transaction holdings fell to 12,489 shares, representing a 17.4% reduction from the 15,122 shares he held before this sale. The recurring pattern of sales at prices significantly above the current market price of $469.34 (the transaction prices were 6.2% above current) is noteworthy, though no measurable outcomes from the prior sales are yet available. With a strong fundamental backdrop (net income of $1,082,900,000.00 on revenue of $3,076,400,000.00 and a P/E ratio of 14.60), the timing and sequence of these concentrated dispositions merit observation by investors tracking executive positioning.

EVP McKechnie Duncan sold 2,437 shares of VRTX at $475.30, reducing holdings 13.9% to 15,122 shares; stock now -11.1% from 52-week high.

McKechnie Duncan, EVP and Chief Commercial Officer, sold 2,437 shares on 2026-03-04 at $475.30, totaling $1,158,306.10. The sale reduced his holdings from 17,559 to 15,122 shares, a 13.9% reduction. The trade occurred as VRTX stock trades $456.69, currently -11.1% from its 52-week high of $513.76, suggesting the insider sold near recent peaks. His prior sell activity at VRTX (two sales on 2026-02-25) is still within their measurement windows with outcomes not yet measurable. The company's fundamentals remain solid with $3.1B quarterly revenue, $1.1B net income, and positive annual growth of 8.9%, alongside a reasonable P/E of 14.21. The open-market sale itself—a material reduction in stake by a senior commercial officer—is a discrete event that warrants tracking, particularly as it follows closely on other recent VRTX sells by this insider.

McKechnie Duncan (Chief Commercial Officer) sells 4,910 shares at blended $487.65 for $2.4M, retains 17.6K shares post-sale

McKechnie Duncan executed 2 separate sales totaling 4,910 shares for $2,394,365.00, reducing his holdings by 21.9% from 22,469 to 17,559 shares. The transactions occurred at prices ($486.35 and $489.00) near the current market price of $480.13, which sits 6.6% below the 52-week high of $513.76. VRTX fundamentals remain solid with annual revenue growth of 8.9%, net income of $1,082,900,000.00, and a P/E of 14.94, providing no obvious deterioration in business conditions. The sale reduces but does not eliminate his material stake in the company, leaving him with substantial ongoing exposure to VRTX.